NVO vs. RPRX: Novo Nordisk vs. Royalty Pharma Stock Comparison

Company Profile

Novo Nordisk (NVO) and Royalty Pharma (RPRX) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Novo Nordisk (NVO) has more than two decades of public-market history since April 30, 1981, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Royalty Pharma (RPRX) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Novo Nordisk (NVO) at 58.38% and Royalty Pharma (RPRX) at 12.09% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Novo Nordisk (NVO) at 33.92% and Royalty Pharma (RPRX) at 25.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Novo Nordisk (NVO) at 40.05% and Royalty Pharma (RPRX) at 81.32% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Novo Nordisk (NVO) at 6.43% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Novo Nordisk (NVO) at 1.77% and Royalty Pharma (RPRX) at 23.09% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Novo Nordisk (NVO) at 0.85 and Royalty Pharma (RPRX) at 1.29 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Novo Nordisk (NVO) at 0.62 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Novo Nordisk (NVO) at 29.03% and Royalty Pharma (RPRX) at 1.37% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Novo Nordisk (NVO) at 45.36% and Royalty Pharma (RPRX) at 60.46% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Novo Nordisk (NVO) at 10.18 sits in the cheaper P/E ratio quartile, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Royalty Pharma (RPRX) at 14.79 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Novo Nordisk (NVO) at 5.43 and Royalty Pharma (RPRX) at 4.39 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics